AKT1 and breast carcinoma: GO‐Y030 inhibits signalling pathways such as IKKβ, STAT3, and AKT, which are crucial for the proliferation and survival of multiple myeloma RPMI8226, KMS12‐BM, and OPM2 cell lines, breast cancer MDA‐MB‐231 cell line, and pancreatic carcinoma PANC‐1, HPAC, and BXPC‐3 cell lines [24, 35].